In deze aflevering
The application of mRNA-based vaccins has shown tremendous value during the corona pandemic. Using this approach for other therapeutic areas as immunology and oncology is now fully being researched by many investigators. RiboPro is a company that is fully dedicated to high quality, high performance RNA. Its founder and CEO, Sander van Asbeck, has the vision that in the future 90% of all diseases can be treated by means of mRNA technologies. He discusses these views and the exciting progress RiboPro is making in this field with Henk Jan Out in the latest podcast of Leaders in Life Sciences.
Sander van Asbeck
Sander van Asbeck is a biomedical scientist by training (Radboud university and Radboudumc, 2008-2017), founder of mRNA-focussed drug-developer Mercurna (2017) and founder & CEO of mRNA-service provider RiboPro (2020). His goal with both companies is to (help) transform medicine with the use of novel genomics-based therapeutics and vaccines. He speaks from a growing background in nanomedicine, messenger RNA and tissue targeting.
